Beijing Sunho Pharmaceutical Co., Ltd

Sunho Pharmaceutical (stock No.: 430017), established in 2000, is an innovative enterprise providing industrialization service for R&D of high-end pharmaceutical dosage forms, which is to provide the customized R&D and production service required for the full life-cycle of a drug product from early clinical research to marketing. Sunho has 4 production sites: Beijing Sunho Pharmaceutical Co., Ltd (headquarters), Beijing Sunho Yingsheng Pharmaceutical Co., Ltd, Guangdong Sunho Pharmaceutical Co., Ltd, and Changchun Tiancheng Pharmaceutical Co., Ltd, whose preparation platforms comply with the China-EU/China-US dual registration standards. And Sunho also has branches in China/Hong Kong, China/US/Europe. Guangdong Sunho Pharmaceutical Co., Ltd., established in 2005, is subordinate to Beijing Sunho Pharmaceutical Co., Ltd and has more than 500 employees. And the company has obtained the GSP certification. Guangdong Sunho has 5 workshops and 14 production lines, covering small-volume injections, freeze-dried powder for injection, conventional tablets, freeze-dried orally disintegrating tablets, microemulsions, BFS products, capsules, etc., providing a one-stop CMC/CMO service of multiple dosage forms, multiple strengths and high capacity for lab-scale, pilot-scale and commercialized production. The workshop producing small-volume injections (terminal sterilization of vials and ampoules) has obtained the EMA certification of Germany and Poland (Certification code: PL/H/0673/001/DC); and the workshop producing small-volume injections and freeze-dried powder for injection (anti-tumor drugs) has submitted the application for the US FDA inspection (Certification code: ANDA213768). Guangdong Sunho Pharmaceutical is a national high-tech enterprise, which has obtained the national project supports from the Ministry of Industry and Information Technology of the People’s Republic of China, the Ministry of Science and Technology of the People’s Republic of China, and the National Development and Reform Commission for many times. Among them, the industrialized CMC/CMO public service platform jointly built with the Shanghai Institute of Material Medical Chinese Academy of Sciences has received the special support for the national biomedical contract R&D and production service platform construction. In recent years, Sunho Pharmaceutical has completed over 100 CMC/CMO projects for nearly a hundred enterprises, including BeiGene, Livzon Pharmaceutical, CR Sanjiu, Huahai Pharmaceutical, Porton Pharmaceutical, North China Pharmaceutical, HEC Pharmaceutical, Sun Novo, Lunan Pharmaceutical, Hybio Pharmaceutical, Lee’s Pharmaceutical, Shanghai Hutchison, Zorun Pharmaceutical, Daguang Group, and Huiyu Pharmaceutical, among which more than 40 are innovative drugs.